# Empagliflozin for No-reflow Phenomenon in PCI for STEMI

> **NCT06342141** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Instituto Nacional de Cardiologia Ignacio Chavez** · enrollment: 162 (estimated)

## Conditions studied

- STEMI
- No-Reflow Phenomenon

## Interventions

- **DRUG:** Empagliflozin 25 milgrams (Mg)
- **DRUG:** Empagliflozin 10 Mg

## Key facts

- **NCT ID:** NCT06342141
- **Lead sponsor:** Instituto Nacional de Cardiologia Ignacio Chavez
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-22
- **Primary completion:** 2026-03-15
- **Final completion:** 2026-06-15
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06342141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06342141, "Empagliflozin for No-reflow Phenomenon in PCI for STEMI". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06342141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*